Normal Tension Glaucoma Treatment
IOP reduction remains the cornerstone of normal tension glaucoma management, with prostaglandin analogues as first-line therapy targeting a 30% reduction from baseline pressure, even though pressures are already in the "normal" range. 1, 2
Treatment Algorithm
1. Establish Target IOP
- Aim for 30% reduction from baseline IOP (not the 20% used for ocular hypertension) 1, 3
- This aggressive target is critical because NTG progresses despite "normal" pressures
- Reassess and lower target further if progression occurs despite initial reduction
2. First-Line Medical Therapy
Start with prostaglandin analogues as initial monotherapy 4, 5, 6:
- Most efficacious IOP-lowering agents (20-30% reduction)
- Once-daily dosing improves adherence
- Best tolerability profile
- Supported by 88% of ophthalmologists as first choice for NTG 6
Recent evidence suggests travoprost and latanoprost rank highest among prostaglandin analogues for long-term NTG control 7
3. Second-Line Options
If prostaglandins are contraindicated or insufficient:
Brimonidine (alpha-2 agonist) 4, 6:
- 10% of ophthalmologists use as first-line
- May have additional neuroprotective properties beyond IOP reduction
- Avoid nighttime dosing
Beta-blockers (timolol, betaxolol) 4:
- Critical caveat: Avoid nighttime dosing—associated with nocturnal blood pressure reduction that may worsen visual field progression 4
- This is particularly important in NTG where vascular factors contribute to disease
4. Adjunctive Agents
Add sequentially if target IOP not achieved:
- Topical carbonic anhydrase inhibitors (dorzolamide, brinzolamide): 15-20% reduction 4
- Rho kinase inhibitors (netarsudil): 10-20% reduction 4
- Oral carbonic anhydrase inhibitors for severe cases: 20-30% reduction 4
5. Emerging Therapy
Palmitoylethanolamide (PEA) shows promise as oral adjunctive therapy with highest efficacy ranking in recent network meta-analysis 7, though this requires further validation before routine clinical use.
Key Clinical Considerations
Vascular Risk Factor Management
NTG pathophysiology involves vascular dysregulation beyond IOP 8, 9, 3, 10:
- Screen for nocturnal hypotension (particularly low diastolic blood pressure)
- Assess for systemic vascular disease, silent cerebral infarcts
- Consider calcium channel blockers in patients with primary vascular dysregulation 3, 10
- Optimize systemic blood pressure—avoid excessive nocturnal drops
Treatment Initiation Threshold
70% of ophthalmologists initiate treatment immediately in mild-to-moderate NTG without waiting for documented progression 6. This aggressive approach is justified because:
- 45% of NTG patients present with severe disease in real-world practice 11
- Progression can be rapid once initiated
- IOP reduction is the only proven intervention to prevent vision loss 1, 2, 9
Monitoring for Progression
- 22% of treated NTG eyes progress despite therapy 11
- Progression rate in advancing cases: -2 dB/year 11
- If progression occurs, lower target IOP further and consider surgical intervention
Common Pitfalls to Avoid
- Do not use beta-blockers at night—this worsens nocturnal perfusion 4
- Do not accept 20% IOP reduction as adequate—NTG requires 30% reduction 1, 3
- Do not delay treatment waiting for progression in moderate disease—most clinicians treat immediately 6
- Do not ignore systemic vascular factors—NTG is likely part of small vessel disease spectrum 8, 10
Surgical Options
Consider laser trabeculoplasty or incisional surgery when:
- Medical therapy fails to achieve target IOP
- Documented progression despite medical management
- Patient adherence issues with medications
- Severe disease at presentation